Major depressive disorder (MDD) and bipolar disorder are among the leading causes of disability worldwide. However, their pathophysiological mechanisms ...

No statistically significant change in MADRS total score was observed with solriamfetol vs placebo in the overall study population. Topline results were announced from a phase 3 trial evaluating ...

Definium Therapeutics (NASDAQ:DFTX) is approaching what Chief Executive Officer Rob Barrow described as an “incredibly ...

Women with MDD who did not use antidepressants had more than twice the risk of breast cancer recurrence as women without MDD. Women with breast cancer who also have major depressive disorder (MDD) ...

Experts recommended individualized MDD relapse prevention, including ECT tapering and pharmacotherapy based on risk profiles.

A study published in the Journal of Affective Disorders proposes a novel, fully automated artificial intelligence (AI) algorithm leveraging ExtraTrees (ET) forests to distinguish patients with major ...

Credit: Otsuka. At this time, the product is available to patients for a discounted price of $50; the full price is $200. Rejoyn ™, the first prescription digital therapeutic cleared for the treatment ...

The use of 42 mg lumateperone combined with antidepressant therapy was linked to significantly reduced severity of depression and anxiety, as well as greater response and remission rates, and was ...

Zachary Contreras of Sharp Health Plan discusses how predictive tools, artificial intelligence-driven analytics, and digital monitoring can help identify treatment-resistant depression early, enabling ...